Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient‐Centered Prescribing

Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.

Authors

Institutions

Publication Details

Journal
Journal of the American Geriatrics Society
Published
2026-10-29
DOI
https://doi.org/10.1111/jgs.70769
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient‐Centered Prescribing

Sarah B. Lieber, Julianna G. Marwell, Elizabeth Eckstrom, Kady Goldlist et al.
4 links
Journal of the American Geriatrics Society
Pharmacology and Obesity Treatment
article

Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient‐Centered Prescribing

Sarah B. Lieber, Julianna G. Marwell, Elizabeth Eckstrom, Kady Goldlist, Emily A. Johnston, John A. Batsis, Suvi Neukam, Elias M. Wisdom, Kamal Chandra Wagle
article en

Abstract

Obesity medications that act through gut-derived hormonal pathways include glucagon-like peptide-1 receptor agonists (GLP-1), dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GLP-1/GIP), and emerging triple glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor agonists. These therapies are increasingly prescribed for weight management and glycemic control, as well as for their cardiometabolic and renal benefits. While these medications offer substantial benefits to patients across multiple health conditions, their use in older adults warrants heightened scrutiny. Older adults face increased risks of sarcopenia and frailty, and evidence from major clinical trials suggests that a substantial proportion of medication-associated weight loss agents may result in loss of lean mass, potentially posing risks for this population. Other adverse effects that may be more consequential in older adults include dehydration, malnutrition, perioperative aspiration, and fat-predominant weight regain after discontinuation. This paper provides a clinically oriented framework to guide prescribing decisions for older adults. Drawing on patient scenarios from common geriatric contexts, including frailty, cognitive impairment, glucocorticoid use, and surgical planning, we propose prescribing approaches that optimize therapeutic benefits while mitigating potential harms. We integrate these recommendations within the Geriatrics 5Ms Framework (Mind, Mobility, Medications, Multicomplexity, and Matters Most) to contextualize treatment within geriatrics practice. Lifestyle co-interventions, particularly resistance training, adequate protein intake, and ongoing functional monitoring, emerge as essential components for older adults receiving these therapies. We also discuss identifying priority areas for future research, including age-stratified clinical trials and the routine inclusion of body composition and physical function outcomes.

Journal of the American Geriatrics Society
University of North Carolina at Chapel Hill (US), Hospital for Special Surgery (US), Hackensack University Medical Center (US), University Health Network (CA), Oregon Health & Science University (US), Duke University (US), University of Toronto (CA), Duke Medical Center (US), Sinai Health System (CA), Weill Cornell Medicine (US), Hackensack Meridian School of Medicine (US), New York University (US)
Good health and well-being
Openalex Percentile: Top 14%
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon